🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchTRIUMPH program (retatrutide) — my results so far Page 4

TRIUMPH program (retatrutide) — my results so far

BenResearch_OR Fri, Jan 31, 2025 at 9:18 PM 42 replies 1,987 viewsPage 4 of 9
rachel_ABQ
Member
178
890
Dec 2024
Albuquerque, NM
Feb 6, 2025 at 5:14 PM#16

Clinical perspective, offered as context rather than as advice. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.

43 16nick_newbie, DadBodDave, AmyNC_wife and 40 others
Reply Quote Save Share Report
tom_AK
New Member
28
112
Jan 2026
Anchorage, AK
Feb 7, 2025 at 12:14 AM#17

A narrower follow-up, since the general answer is now clear:

Did your prescriber agree with that reading, and if not what was their objection?

Last edited: Feb 7, 2025 at 4:14 AM
44 17VanRx_Mike, steve_okc, dave_SLC and 41 others
Reply Quote Save Share Report
kevin_tulsa
Member
489
2,123
Jun 2024
Tulsa, OK
Feb 7, 2025 at 7:14 AM#18
rachel_ABQ said:
The useful move here is to separate what is established from what is widely repeated.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The counter-case has not been addressed. Somebody upthread described the situation that does not fit, and the thread moved on rather than engaging with it, which is the failure mode this board is supposed to avoid.

45 18greg_boulder, quinn_sf, NurseLeah_Nash and 42 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
stefan_berlin
Member
234
1,123
Oct 2024
Berlin, DE
Feb 7, 2025 at 2:14 PM#19
rachel_ABQ said:
The useful move here is to separate what is established from what is widely repeated.

Right, and the exception is worth naming rather than left implied, because the exception is where people get into trouble.

Last edited: Feb 7, 2025 at 5:14 PM
46 19TirzTom, TrialTracker_MD, JennaRN and 43 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Feb 7, 2025 at 9:13 PM#20

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful. Tagging this one for the weekly digest.

Last edited: Feb 7, 2025 at 11:13 PM
18 16PurityPaulOR, MaxMetOK, MounjBrad and 15 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register